WallStSmart

The Cooper Companies, Inc (COO)vsResMed Inc (RMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ResMed Inc generates 30% more annual revenue ($5.40B vs $4.15B). RMD leads profitability with a 27.5% profit margin vs 9.7%. RMD appears more attractively valued with a PEG of 1.39. RMD earns a higher WallStSmart Score of 70/100 (B).

COO

Buy

63

out of 100

Grade: C+

Growth: 6.7Profit: 6.0Value: 8.7Quality: 7.5
Piotroski: 4/9Altman Z: 2.65

RMD

Strong Buy

70

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 8.7Quality: 8.3
Piotroski: 6/9Altman Z: 4.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

COOUndervalued (+11.7%)

Margin of Safety

+11.7%

Fair Value

$94.07

Current Price

$71.45

$22.62 discount

UndervaluedFair: $94.07Overvalued
RMDUndervalued (+14.4%)

Margin of Safety

+14.4%

Fair Value

$303.30

Current Price

$226.31

$76.99 discount

UndervaluedFair: $303.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COO3 strengths · Avg: 8.0/10
Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.8%8/10

Strong operational efficiency at 20.8%

EPS GrowthGrowth
26.9%8/10

Earnings expanding 26.9% YoY

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.7%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
27.5%9/10

Keeps 28 of every $100 in revenue as profit

Areas to Watch

COO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.834/10

Expensive relative to growth rate

P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
4.9%3/10

ROE of 4.9% — below average capital efficiency

RMD0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : COO

The strongest argument for COO centers on Price/Book, Operating Margin, EPS Growth.

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.

Bear Case : COO

The primary concerns for COO are PEG Ratio, P/E Ratio, Return on Equity.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Key Dynamics to Monitor

COO profiles as a value stock while RMD is a mature play — different risk/reward profiles.

COO carries more volatility with a beta of 1.03 — expect wider price swings.

RMD is growing revenue faster at 11.0% — sustainability is the question.

RMD generates stronger free cash flow (311M), providing more financial flexibility.

Bottom Line

RMD scores higher overall (70/100 vs 63/100), backed by strong 27.5% margins and 11.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

The Cooper Companies, Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

The Cooper Companies, Inc., branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California.

Visit Website →

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Want to dig deeper into these stocks?